Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

harmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals and its drug candidate pipeline, including access to presentations made at this and other scientific meetings, please visit http://www.sunesis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the safety and potential efficacy of SNS-595 and SNS-032, planned additional clinical testing and the anticipated timing of the completion of clinical trials and the announcement of clinical results. Words such as "anticipates," "plans," "will," "optimistic," "is expected" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595 and SNS-032 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies and risks related to the
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... St. Jude scientists, findings in ataxia telangiectasia-like ... into the links between brain disease and ... Tenn., Jan. 14 Scientists ... teased apart the biological details distinguishing two ...
... first quarterKENILWORTH, N.J., Jan. 14 Schering-Plough Corporation (NYSE: ... Food and Drug Administration (FDA) has issued a complete ... acute treatment of schizophrenia in adults and in the ... bipolar I disorder in adults as monotherapy. The ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder 2
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) patients ... of life. Some patients have disturbed sleep/wake patterns ... while other patients may be subject to sudden ... PD patients may exhibit REM-sleep behavior disorder (RBD), ... even before motor symptoms appear. A review in ...
(Date:7/10/2014)... the human brain operates much the same whether active ... a better understanding of schizophrenia, bipolar disorder and other ... million Americans. , In newly published research in the ... at the Center for Molecular and Behavioral Neuroscience, determined ... rest is basically the same as that of a ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... Alzheimer's disease and is connected to the same brain pathology. There ... cognitive decline the loss of memory and certain other aspects of ... a normal part of aging, others that it is an early ... it's a disease in its own right. ,A new ...
... the combination of just two genes, according to a new study ... of Clinical Endocrinology and Metabolism this week,// identifies one gene on ... height in men. These genes may also help explain why men ... of both of these genes you will be taller than a ...
... serum concentrations of estrogen and testosterone have about twice ... relatively low serum concentrations of these sex hormones. Associations ... breast cancer were not different in women who donated ... levels in these women were not a preclinical finding. ...
... A new US research has found that young women are ... young men.The study, which contradicts the stereotype that men// are ... The Annals of Internal Medicine this week. ,Researchers from ... years after they were discharged from hospital after a heart ...
... the liver from damage, according to new research from ... laboratory rats. //The rats were then given D-galactosamine, a ... synthesis and results in cell death. The rats fed ... ,The Researchers discovered three new compounds that might ...
... drugs called statins may reduce their risk of developing ... to offer// powerful protection against heart disease for people ... evidence to date that statin drugs may also help ... smaller study had suggested these drugs might offer some ...
Cached Medicine News:
A system for the removal and filtration of laser and surgical smoke....
The FreedomAire Surgical Helmet System is a lightweight, comfortable helmut system with superior air flow, and a removable motor module that lifts off for easy cleaning....
...
... contains these disposable, silver/silver chloride ... separated into eight tabs), two ... patient use only. Starter kit ... red and black, one green ...
Medicine Products: